ClinicalTrials.gg
RecruitingNCT07276581LaunchPAD-RAUpdated Oct 9, 2026

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

A Phase 2 interventional study of AZD1163 and Placebo in Rheumatoid Arthritis, sponsored by AstraZeneca. Recruiting at 147 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 9, 2026Site recruiting status changed3 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Arthritis, Rheumatoid by AstraZeneca — 4 open to participants now, 4 under way, none of them phase 3. Arthritis, Rheumatoid · AstraZeneca.

Planned enrollment
14th of 45
320 · median 72
Started
2025
with 2 others
Phase 2
16 of 49
1 open now
Registered
49th of 49
by date

Among the 49 studies in Arthritis, Rheumatoid by AstraZeneca, this one is the 14th largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2025, is one of 16 in phase 2, and was the 49th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 49 studies in Arthritis, Rheumatoid by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Arthritis, Rheumatoid by AstraZeneca, or all of them as a file.
02

Study summary

Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.

Read the detailed description

AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular peptidyl arginine deiminase 2 (PAD2) and peptidyl arginine deiminase 4 (PAD4) enzymes, which are responsible for protein citrullination. In RA, citrullinated proteins lead to the production of pathogenic anti-citrullinated peptide antibodies (ACPA).

This is a Phase II, randomised, double-blind, multicentre, 4 arm placebo-controlled study designed to evaluate the efficacy and safety of AZD1163 in ACPA + adults with moderate-to-severely active RA on standard of care (SoC) (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs] or tumour necrosis factor inhibitor [TNFi] +/- csDMARD).

The study will have a screening period followed by a randomisation period wherein approximately 320 participants will be randomised in a 1:1:1:1 ratio to receive study intervention.

Participants will receive subcutaneous (SC) injection of one of three different doses of AZD1163 or placebo, along with SoC until Week 24 followed by a safety follow-up (FU) period of 28 weeks.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid arthritis
  • AZD1163
  • placebo-controlled
  • double-blind
  • csDMARDs
  • TNFi
  • PAD2/4 inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening.

    • Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > .
    • Have a positive ACPA at screening.
    • A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi.
    • A history of at least 12 weeks treatment and >= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation.

Exclusion criteria

  • History or evidence of an alternate or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible.

    • Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    AZD1163 Dose 1

    Participants will receive subcutaneous (SC) injection of AZD1163 Dose 1 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24.

    Drug: AZD1163

  • Experimental
    AZD1163 Dose 2

    Participants will receive SC injection of AZD1163 Dose 2 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24.

    Drug: AZD1163

  • Experimental
    AZD1163 Dose 3

    Participants will receive SC injection of AZD1163 Dose 3 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24.

    Drug: AZD1163

  • Placebo comparator
    Placebo

    Participants will receive SC injection of placebo matched with AZD1163 dose in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24.

    Other: Placebo

Interventions

  • DrugAZD1163

    Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24.

  • OtherPlacebo

    Participants will receive SC injection of placebo matched to AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12

    Change from baseline in DAS28-CRP at Week 12.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology Response Criteria 20 (ACR20) at Week 12

    Proportion of participants achieving a 20% improvement in ACR response criteria at Week 12.

    Time frame: Week 12

  2. Percentage of Participants Achieving ACR50 at Week 12

    Proportion of participants achieving a 50% improvement in ACR response criteria at Week 12.

    Time frame: Week 12

  3. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12

    Change from baseline in CDAI at Week 12.

    Time frame: Week 12

  4. Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12

    Change from baseline in SDAI at Week 12.

    Time frame: Week 12

  5. Summary statistics to evaluate the PK of AZD1163

    AZD1163 concentrations in serum

    Time frame: Week 0 to Week 24 and Follow-Up

  6. Summary statistics to evaluate the immunogenicity of AZD1163

    ADA (incidence, prevalence, and titres)

    Time frame: Week 0 to Week 24 and Follow-Up

07

Study locations

117 of 147 sites recruiting
  • Research Site
    Glendale, Arizona 85306, United States
    Recruiting
  • Research Site
    Prescott Valley, Arizona 86314, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Tucson, Arizona 85748, United States
    Recruiting
  • Research Site
    La Jolla, California 92037, United States
    Recruiting
  • Research Site
    San Dimas, California 91773, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    San Leandro, California 94578, United States
    Recruiting
  • Research Site
    Aurora, Colorado 80045, United States
    Recruiting
  • Research Site
    Boynton Beach, Florida 33435, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Jacksonville, Florida 32216, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    South Miami, Florida 33143, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Tampa, Florida 33607, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Winter Haven, Florida 33880, United States
    Recruiting
  • Research Site
    Marietta, Georgia 30060, United States
    Recruiting
  • Research Site
    Skokie, Illinois 60076, United States
    Recruiting
  • Research Site
    Willowbrook, Illinois 60527, United States
    Recruiting
  • Research Site
    Lake Charles, Louisiana 70605, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21224, United States
    Recruiting
  • Research Site
    Rockville, Maryland 20850, United States
    Not yet recruiting
  • Research Site
    New Bedford, Massachusetts 02740, United States
    Recruiting
  • Research Site
    Kansas City, Missouri 64151, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63131, United States
    Recruiting
  • Research Site
    Henderson, Nevada 89052, United States
    Recruiting
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
  • Research Site
    Austin, Texas 78745, United States
    Recruiting
  • Research Site
    Baytown, Texas 77521, United States
    Recruiting
  • Research Site
    Houston, Texas 77027, United States
    Recruiting
  • Research Site
    Houston, Texas 77089, United States
    Recruiting
  • Research Site
    Mesquite, Texas 75150, United States
    Recruiting
  • Research Site
    Tomball, Texas 77375, United States
    Recruiting
  • Research Site
    Caba, C1128AAF, Argentina
    Recruiting
  • Research Site
    Ciudad de Buenos Aires, C1015ABO, Argentina
    Recruiting
  • Research Site
    Ciudad de Buenos Aires, C1428DUQ, Argentina
    Recruiting
  • Research Site
    Córdoba, X5000EDC, Argentina
    Recruiting
  • Research Site
    San Isidro, 1643, Argentina
    Recruiting
  • Research Site
    San Miguel de Tucumán, T4000AXL, Argentina
    Recruiting
  • Research Site
    Juiz de Fora, 36010 570, Brazil
    Not yet recruiting
  • Research Site
    Pelotas, 96040-010, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 90035-903, Brazil
    Recruiting
  • Research Site
    Porto Alegre, 9061-000, Brazil
    Recruiting
  • Research Site
    Salvador, 41820-020, Brazil
    Recruiting
  • Research Site
    São Paulo, 04266-010, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    São Paulo, 05403-000, Brazil
    Not yet recruiting
  • Research Site
    Haskovo, 6304, Bulgaria
    Recruiting
  • Research Site
    Pleven, 5800, Bulgaria
    Recruiting
  • Research Site
    Sofia, 1113, Bulgaria
    Recruiting
  • Research Site
    Sofia, 1336, Bulgaria
    Recruiting
  • Research Site
    Sofia, 1606, Bulgaria
    Recruiting
  • Research Site
    Sofia, 1612, Bulgaria
    Recruiting
  • Research Site
    Niagara Falls, Ontario L2E 6A6, Canada
    Not yet recruiting
  • Research Site
    Ottawa, Ontario K1V 1C1, Canada
    Not yet recruiting
  • Research Site
    Windsor, Ontario N8X 5A7, Canada
    Recruiting
  • Research Site
    Trois-Rivières, Quebec G9A 3Y2, Canada
    Recruiting
  • Research Site
    Providencia, 7510186, Chile
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Santiago, 7500571, Chile
    Recruiting
  • Research Site
    Santiago, 7500587, Chile
    Recruiting
  • Research Site
    Temuco, 4810345, Chile
    Recruiting
  • Research Site
    Valdivia, 5110683, Chile
    Recruiting
  • Research Site
    Victoria, 4720097, Chile
    Recruiting
  • Research Site
    Viña del Mar, 2531172, Chile
    Recruiting
  • Research Site
    Beijing, 100144, China
    Recruiting
  • Research Site
    Beijing, 100730, China
    Recruiting
  • Research Site
    Changchun, 130021, China
    Recruiting
  • Research Site
    Changsha, 410008, China
    Recruiting
  • Research Site
    Guangzhou, 510515, China
    Recruiting
  • Research Site
    Jiujiang, 332000, China
    Recruiting
  • Research Site
    Kunming, 650032, China
    Not yet recruiting
  • Research Site
    Linyi, CN-276003, China
    Recruiting
  • Research Site
    Nanchong, 637000, China
    Recruiting
  • Research Site
    Panjin, 124000, China
    Recruiting
  • Research Site
    Pingxiang, 337055, China
    Recruiting
  • Research Site
    Shantou, 515041, China
    Recruiting
  • Research Site
    Xuzhou, 221009, China
    Recruiting
  • Research Site
    Yangzhou, 225001, China
    Recruiting
  • Research Site
    Zhengzhou, 450000, China
    Recruiting
  • Research Site
    Bad Doberan, 18209, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Berlin, 10777, Germany
    Recruiting
  • Research Site
    Hamburg, 20095, Germany
    Recruiting
  • Research Site
    Sendenhorst, 48324, Germany
    Recruiting
  • Research Site
    Budapest, 1023, Hungary
    Recruiting
  • Research Site
    Budapest, 1027, Hungary
    Recruiting
  • Research Site
    Budapest, 1036, Hungary
    Not yet recruiting
  • Research Site
    Debrecen, 4032, Hungary
    Recruiting
  • Research Site
    Gyula, 5700, Hungary
    Recruiting
  • Research Site
    Szeged, 6725, Hungary
    Recruiting
  • Research Site
    Székesfehérvár, 8000, Hungary
    Recruiting
  • Research Site
    Veszprém, 8200, Hungary
    Recruiting
  • Research Site
    Aomori, 030-8553, Japan
    Recruiting
  • Research Site
    Bunkyō City, 113-8655, Japan
    Recruiting
  • Research Site
    Fukuoka, 815-8555, Japan
    Recruiting
  • Research Site
    Hamamatsu, 430-0906, Japan
    Recruiting
  • Research Site
    Hitachi-Naka, 312-0057, Japan
    Recruiting
  • Research Site
    Iizuka-shi, 820-8505, Japan
    Recruiting
  • Research Site
    Kawachinagano-shi, 586-8521, Japan
    Recruiting
  • Research Site
    Matsuyama, 790-8524, Japan
    Recruiting
  • Research Site
    Meguro-ku, 152-8902, Japan
    Recruiting
  • Research Site
    Miyazaki, 880-0834, Japan
    Recruiting
  • Research Site
    Nagoya, 457-8511, Japan
    Recruiting
  • Research Site
    Okayama, 700-8557, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Sagamihara-shi, 252-0315, Japan
    Recruiting
  • Research Site
    Sapporo, 060-0001, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

Showing the first 100 of 147 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 22 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 22 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 11, 2025
StartActual
Dec 15, 2025
Primary completionEst.
Nov 12, 2027
CompletionEst.
Aug 18, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. 66 sites changed recruiting status (63 now recruiting, 3 now withdrawn)
Show 66 sites
  • Research Site · Glendale, United StatesNot yet recruiting→Recruiting
  • Research Site · Tucson, United StatesNot yet recruiting→Recruiting
  • Research Site · La Jolla, United StatesNot yet recruiting→Recruiting
  • Research Site · San Leandro, United StatesNot yet recruiting→Recruiting
  • Research Site · Aurora, United StatesNot yet recruiting→Recruiting
  • Research Site · Winter Haven, United StatesNot yet recruiting→Recruiting
  • Research Site · Marietta, United StatesNot yet recruiting→Recruiting
  • Research Site · Skokie, United StatesNot yet recruiting→Recruiting
  • Research Site · Baltimore, United StatesNot yet recruiting→Recruiting
  • Research Site · Kansas City, United StatesNot yet recruiting→Recruiting
  • Research Site · Myrtle Beach, United StatesNot yet recruiting→Recruiting
  • Research Site · Mesquite, United StatesNot yet recruiting→Recruiting
  • Research Site · Ciudad de Buenos Aires, ArgentinaNot yet recruiting→Recruiting
  • Research Site · Pelotas, BrazilNot yet recruiting→Recruiting
  • Research Site · Porto Alegre, BrazilNot yet recruiting→Recruiting
  • Research Site · Salvador, BrazilNot yet recruiting→Recruiting
  • Research Site · Haskovo, BulgariaNot yet recruiting→Recruiting
  • Research Site · Pleven, BulgariaNot yet recruiting→Recruiting
  • Research Site · Sofia, BulgariaNot yet recruiting→Recruiting
  • Research Site · Providencia, ChileNot yet recruiting→Withdrawn
  • Research Site · Santiago, ChileNot yet recruiting→Recruiting
  • Research Site · Temuco, ChileNot yet recruiting→Recruiting
  • Research Site · Valdivia, ChileNot yet recruiting→Recruiting
  • Research Site · Victoria, ChileNot yet recruiting→Recruiting
  • Research Site · Viña del Mar, ChileNot yet recruiting→Recruiting
  • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
  • Research Site · Changchun, ChinaNot yet recruiting→Recruiting
  • Research Site · Changsha, ChinaNot yet recruiting→Recruiting
  • Research Site · Guangzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Jiujiang, ChinaNot yet recruiting→Recruiting
  • …and 36 more on the registry record
Show 3 added (2 Canada, 1 United States)
  • Research Site · Rockville, United States
  • Research Site · Niagara Falls, Canada
  • Research Site · Ottawa, Canada
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    3 sites added. 75 sites changed recruiting status (72 now recruiting, 3 now withdrawn)
    Show 75 sites
    • Research Site · Glendale, United StatesNot yet recruiting→Recruiting
    • Research Site · Tucson, United StatesNot yet recruiting→Recruiting
    • Research Site · La Jolla, United StatesNot yet recruiting→Recruiting
    • Research Site · San Leandro, United StatesNot yet recruiting→Recruiting
    • Research Site · Aurora, United StatesNot yet recruiting→Recruiting
    • Research Site · Winter Haven, United StatesNot yet recruiting→Recruiting
    • Research Site · Marietta, United StatesNot yet recruiting→Recruiting
    • Research Site · Skokie, United StatesNot yet recruiting→Recruiting
    • Research Site · Baltimore, United StatesNot yet recruiting→Recruiting
    • Research Site · Kansas City, United StatesNot yet recruiting→Recruiting
    • Research Site · Myrtle Beach, United StatesNot yet recruiting→Recruiting
    • Research Site · Mesquite, United StatesNot yet recruiting→Recruiting
    • Research Site · Ciudad de Buenos Aires, ArgentinaNot yet recruiting→Recruiting
    • Research Site · Pelotas, BrazilNot yet recruiting→Recruiting
    • Research Site · Porto Alegre, BrazilNot yet recruiting→Recruiting
    • Research Site · Porto Alegre, BrazilNot yet recruiting→Recruiting
    • Research Site · Salvador, BrazilNot yet recruiting→Recruiting
    • Research Site · Haskovo, BulgariaNot yet recruiting→Recruiting
    • Research Site · Pleven, BulgariaNot yet recruiting→Recruiting
    • Research Site · Sofia, BulgariaNot yet recruiting→Recruiting
    • Research Site · Sofia, BulgariaNot yet recruiting→Recruiting
    • Research Site · Sofia, BulgariaNot yet recruiting→Recruiting
    • Research Site · Sofia, BulgariaNot yet recruiting→Recruiting
    • Research Site · Providencia, ChileNot yet recruiting→Withdrawn
    • Research Site · Santiago, ChileNot yet recruiting→Recruiting
    • Research Site · Santiago, ChileNot yet recruiting→Recruiting
    • Research Site · Temuco, ChileNot yet recruiting→Recruiting
    • Research Site · Valdivia, ChileNot yet recruiting→Recruiting
    • Research Site · Victoria, ChileNot yet recruiting→Recruiting
    • Research Site · Viña del Mar, ChileNot yet recruiting→Recruiting
    • …and 45 more on the registry record
    Show 3 added (2 Canada, 1 United States)
    • Research Site · Rockville, United States
    • Research Site · Niagara Falls, Canada
    • Research Site · Ottawa, Canada
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07276581
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Dec 15, 2025
Primary completion
Nov 12, 2027 (estimated)
Completion
Aug 18, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion